176 related articles for article (PubMed ID: 36062458)
41. Visual outcome measures in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
Gericke FC; Hanson JVM; Hackenberg A; Gerth-Kahlert C
Eur J Paediatr Neurol; 2024 Jan; 48():113-120. PubMed ID: 38217965
[TBL] [Abstract][Full Text] [Related]
42. Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging.
Cortese R; Prados Carrasco F; Tur C; Bianchi A; Brownlee W; De Angelis F; De La Paz I; Grussu F; Haider L; Jacob A; Kanber B; Magnollay L; Nicholas RS; Trip A; Yiannakas M; Toosy AT; Hacohen Y; Barkhof F; Ciccarelli O
Neurology; 2023 Jan; 100(3):e308-e323. PubMed ID: 36192175
[TBL] [Abstract][Full Text] [Related]
43. Quantifying visual pathway axonal and myelin loss in multiple sclerosis and neuromyelitis optica.
Manogaran P; Vavasour IM; Lange AP; Zhao Y; McMullen K; Rauscher A; Carruthers R; Li DKB; Traboulsee AL; Kolind SH
Neuroimage Clin; 2016; 11():743-750. PubMed ID: 27330974
[TBL] [Abstract][Full Text] [Related]
44. MRI characteristics of MOG-Ab associated disease in adults: An update.
Shor N; Deschamps R; Cobo Calvo A; Maillart E; Zephir H; Ciron J; Papeix C; Durand-Dubief F; Ruet A; Ayrignac X; Cohen M; Deiva K; Laplaud D; Bourre B; Audoin B; Collongues N; Vukusic S; Cotton F; Marignier R;
Rev Neurol (Paris); 2021; 177(1-2):39-50. PubMed ID: 33046261
[TBL] [Abstract][Full Text] [Related]
45. Optic chiasm involvement in AQP-4 antibody-positive NMO and MOG antibody-associated disorder.
Tajfirouz D; Padungkiatsagul T; Beres S; Moss HE; Pittock S; Flanagan E; Kunchok A; Shah S; Bhatti MT; Chen JJ
Mult Scler; 2022 Jan; 28(1):149-153. PubMed ID: 33975499
[TBL] [Abstract][Full Text] [Related]
46. Neuro-ophthalmological Presentation of Optic Neuritis in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Lin TY; Asseyer S; Buenrostro GS; Feldmann K; Hamann S; Paul F; Zimmermann HG
Klin Monbl Augenheilkd; 2022 Nov; 239(11):1305-1314. PubMed ID: 35995144
[TBL] [Abstract][Full Text] [Related]
47. Changes of retinal structure and visual function in patients with demyelinating transverse myelitis.
Lee JH; Moon Y; Kwon YN; Shin JH; Kim SM; Jung JH
Neurol Sci; 2022 Nov; 43(11):6425-6431. PubMed ID: 35939134
[TBL] [Abstract][Full Text] [Related]
48. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment.
Gospe SM; Chen JJ; Bhatti MT
Eye (Lond); 2021 Mar; 35(3):753-768. PubMed ID: 33323985
[TBL] [Abstract][Full Text] [Related]
49. Initial Pattern of Optic Nerve Enhancement in Korean Patients with Unilateral Optic Neuritis.
Son DY; Park KA; Seok SS; Lee JY; Oh SY
Korean J Ophthalmol; 2017 Feb; 31(1):71-79. PubMed ID: 28243026
[TBL] [Abstract][Full Text] [Related]
50. [Typical and atypical optic neuritis].
Sheremet NL; Eliseeva DD; Kalashnikova AK; Zakharova MN
Vestn Oftalmol; 2023; 139(6):175-182. PubMed ID: 38235645
[TBL] [Abstract][Full Text] [Related]
51. [Anti-MOG antibody in different types of immune-mediated optic neuritis].
Kong XY; Peng JT; Liu LJ; Yan R; Zhang XJ
Zhonghua Yan Ke Za Zhi; 2012 Dec; 48(12):1069-72. PubMed ID: 23336409
[TBL] [Abstract][Full Text] [Related]
52. Dual positivity for anti-MOG and oligoclonal bands: Unveiling unique clinical profiles and implications.
Ganelin-Cohen E; Shelly S; Schiller Y; Vaknin-Dembinsky A; Shachor M; Rechtman A; Osherov M; Duvdevan N; Rozenberg A
Mult Scler Relat Disord; 2023 Nov; 79():105034. PubMed ID: 37801958
[TBL] [Abstract][Full Text] [Related]
53. Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis.
Tajfirouz DA; Bhatti MT; Chen JJ
Curr Neurol Neurosci Rep; 2019 Nov; 19(12):100. PubMed ID: 31773369
[TBL] [Abstract][Full Text] [Related]
54. First-ever optic neuritis: distinguishing subsequent neuromyelitis optica from multiple sclerosis.
Lim YM; Pyun SY; Lim HT; Jeong IH; Kim KK
Neurol Sci; 2014 May; 35(5):781-3. PubMed ID: 24487628
[TBL] [Abstract][Full Text] [Related]
55. Clinical features of COVID-19-related optic neuritis: a retrospective study.
Zhao FF; Wang Y; Li TP; Hu S; Yu XS; Li X; Cen J; Huang K; Lin H; Yang JF; Chen L; Cen LP
Front Neurol; 2024; 15():1365465. PubMed ID: 38682033
[TBL] [Abstract][Full Text] [Related]
56. Clinical and MRI phenotype of children with MOG antibodies.
Fernandez-Carbonell C; Vargas-Lowy D; Musallam A; Healy B; McLaughlin K; Wucherpfennig KW; Chitnis T
Mult Scler; 2016 Feb; 22(2):174-84. PubMed ID: 26041801
[TBL] [Abstract][Full Text] [Related]
57. Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis.
Messina S; Mariano R; Roca-Fernandez A; Cavey A; Jurynczyk M; Leite MI; Calabrese M; Jenkinson M; Palace J
Mult Scler; 2022 Feb; 28(2):217-227. PubMed ID: 34048323
[TBL] [Abstract][Full Text] [Related]
58. Cerebrospinal fluid eosinophils in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease.
Kornbluh AB; Campano VM; Har C; Dwivedi P; Suslovic W; Sepeta L; Kahn I
Mult Scler Relat Disord; 2024 May; 85():105526. PubMed ID: 38489945
[TBL] [Abstract][Full Text] [Related]
59. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients.
Jarius S; Lechner C; Wendel EM; Baumann M; Breu M; Schimmel M; Karenfort M; Marina AD; Merkenschlager A; Thiels C; Blaschek A; Salandin M; Leiz S; Leypoldt F; Pschibul A; Hackenberg A; Hahn A; Syrbe S; Strautmanis J; Häusler M; Krieg P; Eisenkölbl A; Stoffels J; Eckenweiler M; Ayzenberg I; Haas J; Höftberger R; Kleiter I; Korporal-Kuhnke M; Ringelstein M; Ruprecht K; Siebert N; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B; Rostásy K;
J Neuroinflammation; 2020 Sep; 17(1):262. PubMed ID: 32883358
[TBL] [Abstract][Full Text] [Related]
60. Relapsing MRI-negative myelitis associated with myelin-oligodendrocyte glycoprotein autoantibodies: a case report.
Kolcava J; Rajdova A; Vlckova E; Stourac P; Bednarik J
BMC Neurol; 2022 Aug; 22(1):313. PubMed ID: 36002821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
